北京中因制药

Beijing Sino-Cause Pharmaceutical is a clinical-stage biotechnology company focused on the research and development of gene therapies for inherited retinal diseases (IRDs). The company utilizes a proprietary AAV vector platform and gene editing technologies to develop treatments for conditions such as Leber congenital amaurosis and Retinitis pigmentosa. Its lead program, ZVS101e, is an AAV-mediated gene replacement therapy targeting RPE65 mutations and is currently in clinical development in China. Sino-Cause aims to address the significant unmet need for genetic eye disorders through its specialized pipeline, academic collaborations with Peking University, and in-house GMP manufacturing capabilities.